TRPV4 Agonist Targeting Primary Cilia for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma primarily focus on lowering intraocular pressure, but they often lead to side effects and eventually lose effectiveness, necessitating surgical intervention, and the molecular mechanisms behind elevated pressure leading to vision loss are not well understood.
Innovation Solution
Administering TRPV4 agonists to individuals in need, specifically targeting the trabecular meshwork cells to regulate intraocular pressure and address ciliopathy-related issues, including glaucoma, by modulating ciliary function and mechanosensory signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If conventional glaucoma treatments are administered to lower intraocular pressure, then intraocular pressure is reduced, but side effects occur and effectiveness is lost over time
Solution Approach 1:
The patent changes the molecular target parameter from conventional pressure-lowering drugs to TRPV4 channel agonists. This parameter change enables a new mechanism of action that modulates ciliary function and mechanosensory signaling, potentially providing sustained effectiveness without the side effects and tolerance development associated with conventional treatments.
Solution Approach 2:
The patent introduces TRPV4 channels as an intermediary mechanism between pressure sensing and aqueous humor drainage. By activating TRPV4 channels in trabecular meshwork cells, the treatment modulates the mechanosensory signaling pathway that regulates fluid outflow, providing a more precise and sustainable control of intraocular pressure.
2Stress or pressure
If conventional glaucoma treatments are used to reduce eye pressure, then intraocular pressure is lowered, but surgical intervention is eventually required
Solution Approach 1:
The patent replaces the need for surgical intervention with a pharmacological mechanism that targets molecular pathways. By using TRPV4 channel agonists to modulate ciliary function and mechanosensory signaling, the treatment provides a non-invasive alternative that can sustainably control intraocular pressure without requiring surgical procedures.
3Reliability
If the molecular mechanisms of elevated pressure are not understood, then treatment targets are limited, but understanding these mechanisms would enable more effective treatments
Solution Approach 1:
The patent employs feedback from molecular mechanism research to guide treatment development. By understanding how elevated pressure affects ciliary function and mechanosensory signaling, the treatment design incorporates TRPV4 channel activation as a feedback mechanism to restore normal pressure regulation, thereby achieving more effective and targeted therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces intraocular pressure, treats glaucoma, and addresses ciliopathy-related dysregulation, potentially preventing vision loss and blindness by targeting the underlying ciliary mechanisms.
Implementation Method 1
TRPV4 protein is a Ca2+-permeable, nonselective cation channel that is thought to be involved in the regulation of systemic osmotic pressure
Implementation Method 2
Upon extracellular stimulation, TRP channels initiate signal transduction cascades by inducing Ca2+ flow
Implementation Method 3
TRPV4 also functions as a ciliary mechanosensory channel
Implementation Method 4
Mechanosensation of pressure underlies a number of important human diseases including the development of hypertension and glaucoma
Implementation Method 5
Phosphoinositides within the ciliary membrane are essential secondary messengers for ciliary function, potentially through modulation of the activities of TRP channels
Data Source
AI summary
Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.